Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

Inclusion Criteria: * Patients with clinically diagnosed influenza, body temperature ≥ 38 ºС or other acute respiratory viral infection, body temperature ≥ 37 ºС, with no less than 2 symptoms of catarrhal and intoxication each: * Intoxication symptoms: Dizziness, headache, chills, fever, sweating, fatigue, myalgia, pain while moving eyes, flushing, pale skin, sleep disturbances, decreased appetite, nausea, vomiting, epistaxis, cyanosis, meningeal signs. * Catarrhal symptoms: Sore throat, rhinorrhea and nasal congestion, difficulty swallowing, hoarseness, stridor, wheezing, rattling dry and wet cough, expectoration. * Laboratory confirmation of viral origin of the disease * Uncomplicated influenza and other acute respiratory viral infections * Interval between onset of symptoms and enrollment to the study not more than 48 hours * Have read, understood and signed an informed consent form Exclusion Criteria: * Complicated course of influenza and other acute respiratory viral infections (secondary bacterial infection) * Pregnancy and Breastfeeding * Severe decompensated or unstable medical or psychiatric conditions (any diseases or conditions that threaten the life of the patient or worsen the patient's prognosis) * Cancer, HIV infection, tuberculosis, including those in history * History of alcohol and drug abuse